JOURNAL CONTENT
CONTACT

Submission of the manuscript is online via e-mail
ecgarticle@gmail.com or
cholerez@mail.ru

Tel: +7 903 250 5288

Editorial Correspondence e-mail
gastrossr@gmail.com


Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail
journal@cniig.ru

Tel: +7 917 561 9505

THE RULES OF SUBMITTING AN ARTICLE

READ

Scimago Journal & Country Rank

SCImago Journal & Country Rank

REVIEW

    1. State Scientifi c Center of Coloproctology, 123423, Moscow, Russia, st. Salam Adil, 2
    2. Faculty of advanced training of medical workers Peoples' Friendship University of Russia, 117198, Moscow, st. Miklukho-Maklaya, 21, 3
    3. City Polyclinic № 218 DZM, branch number 3 in Losinoostrovsky district, 1-ya Naprudnaya street, 15
    4. Federal state budgetary educational institution additional professional education Ministry of Health of Russia, 125993, Moscow, Russia, st. Barrikadnaya, d. 2⁄1, p. 1

    Keywords: Clostridium (Clostridioides) diffi cile, C. diffi cile-associated infection, antibiotic resistance, mechanisms of antibacterial resistance

    Abstract:Aim of the review. To study and consolidate recent data on Clostridium (Clostridioides) diffi cile antibacterial resistance mechanisms. Key points. There is objective data about the spread of antimicrobial resistant Clostridium (Clostridioides) diffi cile strains. Mechanisms of antimicrobial resistance in bacteria determined by genetic resistance or metabolic pathways are described. Spread of antimicrobial resistance in clinically relevant С. diffi cile is aggravated by its ability to form biofi lms. Moreover, being a spore-forming bacterium, С. diffi cile can resist microbicidal action staying in the form of spore. After antibiotic cessation С. diffi cile returns to vegetative state and causes recurrence of thee disease. Understanding of С. diffi cile antibacterial resistance mechanisms is one of the key points in disease prevention strategy. Besides antibiotic stewardship, monitoring for the С. diffi cile antibacterial resistance spread is needed. We argue that the research on С. diffi cile antibacterial resistance and on the development of novel antibacterial agents eff ective against С. diffi cile must be continued.

      1. Mulyar N. F., Vereschagina S. A., Fadeeva T. V., et al. Clostridium diffi cile associated diarrhea in multidisciplinary hospital. Acta biomedica scientifi ca. 2012, no. 5–1 (87), pp. 72–75.
      2. Dmitrieva N. V., Klyasova G. A., Bakulina N. V., et al. A prevalence of Clostridium diffi cileassociated diarrhea in hospitalized patients (results of a Russian prospective multicenter study). Clinical Microbiology and Antimicrobial Chemotherapy (CMAC). 2017;19(4):268–274.
      3. Safi n A. L., Achkasov S. I., Sukhina M. A., Sushkov O. I. Risk factors for diarrhea associated with сlostridium diffi cile, in coloproctological patients (review). Koloproktologia. 2017, no. 1, pp. 59–67.
      4. Kwon J. H., Olsen M. A., Dubberke E. R. Th e morbidity, mortality, and costs associated with Clostridium diffi cile infection //Infectious disease clinics of North America. – 2015. – Т. 29. – № 1. – С. 123–134.
      5. McGlone, S. M., Bailey, R. R., Zimmer, S. et al. Th e economic burden of Clostridium diffi cile //Clinical Microbiology and Infection. – 2012. – Т. 18. – № 3. – С. 282–289.
      6. Kirgizov K. I., Shulga S. Y., Pristanskova Y. A., Konstantinova V. V., Gerasimova Y. V., Sidorova N. V., Blagonravova O. L., Fedorova N. I., Skorobogatova Y. V. Is Clostridium diffi cule-associated enterocolitis in pediatric hematology/oncology a solved problem? A review of literature and the authors’ experience. Russian Journal of Pediatric Hematology and Oncology. 2014;(1):25–31. (In Russ.) https://doi.org/10.17650/2311–1267–2014– 0–1–25–31
      7. O’Connor, J. R., Galang, M. A., Sambol, S. P. et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium diffi cile //Antimicrobial agents and chemotherapy. – 2008. – Т. 52. – № 8. – С. 2813–2817.
      8. Bagdasarian N., Rao K., Malani P. N. Diagnosis and treatment of Clostridium diffi cile in adults: a systematic review //Jama. – 2015. – Т. 313. – № 4. – С. 398–408.
      9. Spigaglia, P., Barbanti, F., Mastrantonio, P. et al. Multidrug resistance in European Clostridium diffi cile clinical isolates //Journal of antimicrobial chemotherapy. – 2011. – Т. 66. – № 10. – С. 2227–2234.
      10. Lynch, T., Chong, P., Zhang, J. et al. Characterization of a stable, metronidazole-resistant Clostridium diffi cile clinical isolate //PLoS One. – 2013. – Т. 8. – № 1. – С. e53757.
      11. Dingle, K. E., Elliott, B., Robinson, E. et al. Evolutionary history of the Clostridium diffi cile pathogenicity locus // Genome biology and evolution. – 2013. – Т. 6. – № 1. – С. 36–52.
      12. Linkevicius M., Sandegren L., Andersson D. I. Potential of tetracycline resistance proteins to evolve tigecycline resistance //Antimicrobial agents and chemotherapy. – 2016. – Т. 60. – № 2. – С. 789–796.
      13. Spigaglia, P., Barbanti, F., Mastrantonio, P. et al. Fluoroquinolone resistance in Clostridium diffi cile isolates from Journal of medical microbiology. – 2008. – Т. 57. – № 6. – С. 784–789.
      14. Freeman, J., Baines, S. D., Jabes, D. et al. Comparison of the effi cacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium diffi cile infection //Journal of Antimicrobial Chemotherapy. – 2005. – Т. 56. – № 4. – С. 717–725.
      15. Shen J., Wang Y., Schwarz S. Presence and dissemination of the multiresistance gene cfr in Gram-positive and Gram-negative bacteria //Journal of Antimicrobial Chemotherapy. – 2013. – Т. 68. – № 8. – С. 1697–1706.
      16. Snydman, D. R., McDermott, L. A., Jacobus, N. V. et al. US-based national sentinel surveillance study for the epidemiology of Clostridium diffi cile-associated diarrheal isolates and their susceptibility to fi daxomicin // Antimicrobial agents and chemotherapy. – 2015. – Т. 59. – № 10. – С. 6437–6443.
      17. Peltier, J., Courtin, P., El Meouche, I. et al. Genomic and expression analysis of the vanG-like gene cluster of Clostridium diffi cile //Microbiology. – 2013. – Т. 159. – № 7. – С. 1510–1520.
      18. Spigaglia P. Recent advances in the understanding of antibiotic resistance in Clostridium diffi cile infection // Th erapeutic advances in infectious disease. – 2016. – Т. 3. – № 1. – С. 23–42.
      19. He, M., Miyajima, F., Roberts, P. et al. Emergence and global spread of epidemic healthcare-associated Clostridium diffi cile //Nature genetics. – 2013. – Т. 45. – № 1. – С. 109.
      20. Keessen, E. C., Hensgens, M. P., Spigaglia, P. et al. Antimicrobial susceptibility profi les of human and piglet Clostridium diffi cile PCR-ribotype 078 //Antimicrobial resistance and infection control. – 2013. – Т. 2. – № 1. – С. 14.
      21. Cohen, S. H., Gerding, D. N., Johnson, S. et al. Clinical practice guidelines for Clostridium diffi cile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA) //Infection Control & Hospital Epidemiology. – 2010. – Т. 31. – № 5. – С. 431–455.
      22. Goudarzi, M., Goudarzi, H., Alebouyeh, M. et al. Antimicrobial susceptibility of Clostridium diffi cile clinical isolates in Iran //Iranian Red Crescent Medical Journal. – 2013. – Т. 15. – № 8. – С. 704.
      23. Adler, A., Miller-Roll, T., Bradenstein, R et al. A national survey of the molecular epidemiology of Clostridium diffi cile in Israel: the dissemination of the ribotype 027 strain with reduced susceptibility to vancomycin and metronidazole //Diagnostic microbiology and infectious disease. – 2015. – Т. 83. – № 1. – С. 21–24.
      24. Freeman, J., Vernon, J., Morris, K. et al. Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium diffi cile ribotypes //Clinical Microbiology and Infection. – 2015. – Т. 21. – № 3. – С. 248. e9–248. e16.
      25. Jin, D., Luo, Y., Huang, C. et al. Molecular epidemiology of Clostridium diffi cile infection in hospitalized patients in Eastern China //Journal of clinical microbiology. – 2017. – Т. 55. – № 3. – С. 801–810.
      26. Ofosu A. Clostridium diffi cile infection: a review of current and emerging therapies //Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology. – 2016. – Т. 29. – № 2. – С. 147.
      27. Moura, I., Spigaglia, P., Barbanti, F., Mastrantonio, P. Analysis of metronidazole susceptibility in diff erent Clostridium diffi cile PCR ribotypes //Journal of Antimicrobial Chemotherapy. – 2012. – Т. 68. – № 2. – С. 362–365.
      28. Goudarzi, M., Goudarzi, H., Alebouyeh, M. et al. Antimicrobial susceptibility of Clostridium diffi cile clinical isolates in Iran //Iranian Red Crescent Medical Journal. – 2013. – Т. 15. – № 8. – С. 704.
      29. Peng, Z., Jin, D., Kim, H. B. et al. Update on antimicrobial resistance in Clostridium diffi cile: resistance mechanisms and antimicrobial susceptibility testing // Journal of clinical microbiology. – 2017. – Т. 55. – № 7. – С. 1998–2008.
      30. Cheng, J. W., Xiao, M., Kudinha, T., et al. Molecular epidemiology and antimicrobial susceptibility of Clostridium diffi cile isolates from a university teaching hospital in China //Frontiers in microbiology. – 2016. – Т. 7. – С. 1621.
      31. Leeds, J. A., Sachdeva, M., Mullin, S. et al. In vitro selection, via serial passage, of Clostridium diffi cile mutants with reduced susceptibility to fi daxomicin or vancomycin //Journal of Antimicrobial Chemotherapy. – 2013. – Т. 69. – № 1. – С. 41–44.
      32. Goldstein E. J. C., Babakhani F., Citron D. M. Antimicrobial activities of fi daxomicin //Clinical infectious diseases. – 2012. – Т. 55. – № suppl_2. – С. S143-S148.
      33. Kelly C. P., LaMont J. T. Clostridium diffi cile infection // Annual review of medicine. – 1998. – Т. 49. – № 1. – С. 375– 390.
      34. Cohen, S. H., Gerding, D. N., Johnson, S. et al. Clinical practice guidelines for Clostridium diffi cile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA) //Infection Control & Hospital Epidemiology. – 2010. – Т. 31. – № 5. – С. 431–455.
      35. Walkty, A., Boyd, D. A., Gravel, D. et al. Molecular characterization of moxifl oxacin resistance from Canadian Clostridium diffi cile clinical isolates //Diagnostic microbiology and infectious disease. – 2010. – Т. 66. – № 4. – С. 419–424.
      36. Wasels, F., Spigaglia, P., Barbanti, F., & Mastrantonio, P. Clostridium diffi cile erm (B)-containing elements and the burden on the in vitro fi tness //Journal of medical microbiology. – 2013. – Т. 62. – № 9. – С. 1461–1467.
      37. Rineh, A., Kelso, M. J., Vatansever, F. et al. Clostridium diffi cile infection: molecular pathogenesis and novel therapeutics //Expert review of anti-infective therapy. – 2014. – Т. 12. – № 1. – С. 131–150.
      38. Fry P. R., Th akur S., Gebreyes W. A. Antimicrobial resistance, toxinotype and genotypic profi ling of Clostridium diffi cile of swine origin //Journal of clinical microbiology. – 2012. – С. JCM. 06581–11.
      39. Kali A., Charles M. V. P., Srirangaraj S. Cadazolid: a new hope in the treatment of Clostridium diffi cile infection // Th e Australasian medical journal. – 2015. – Т. 8. – № 8. – С. 253.
      40. Norén, T., Alriksson, I., Åkerlund, T. et al. In vitro susceptibility to 17 antimicrobials of clinical Clostridium diffi cile isolates collected in 1993–2007 in Sweden // Clinical Microbiology and Infection. – 2010. – Т. 16. – № 8. – С. 1104–1110.
      41. Chong, P. M., Lynch, T., McCorrister, S. et al. Proteomic analysis of a NAP1 Clostridium diffi cile clinical isolate resistant to metronidazole //PloS one. – 2014. – Т. 9. – № 1. – С. e82622.
      42. Peng, Z., Addisu, A., Alrabaa, S., Sun, X. Antibiotic resistance and toxin production of Clostridium diffi cile isolates from the hospitalized patients in a large hospital in Florida //Frontiers in microbiology. – 2017. – Т. 8.
      43. Ðapa, T., Leuzzi, R., Ng, Y. K. et al. Multiple factors modulate biofi lm formation by the anaerobic pathogen Clostridium diffi cile //Journal of bacteriology. – 2013. – Т. 195. – № 3. – С. 545–555.
      44. Tyrrell, K. L., Citron, D. M., Warren, Y. A. et al. In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium diffi cile, C. perfringens, Finegoldia magna, and Propionibacterium acnes //Antimicrobial agents and chemotherapy. – 2006. – Т. 50. – № 8. – С. 2728–2731
      45. Moura, I., Monot, M., Tani, C. et al. Multidisciplinary analysis of a nontoxigenic Clostridium diffi cile strain with stable resistance to metronidazole //Antimicrobial agents and chemotherapy. – 2014. – Т. 58. – № 8. – С. 4957–4960.
      46. Land K. M., Johnson P. J. Molecular basis of metronidazole resistance in pathogenic bacteria and protozoa //Drug Resistance Updates. – 1999. – Т. 2. – № 5. – С. 289–294.
      47. Baines S. D., Wilcox M. H. Antimicrobial resistance and reduced susceptibility in Clostridium diffi cile: potential consequences for induction, treatment, and recurrence of C. diffi cile infection //Antibiotics. – 2015. – Т. 4. – № 3. – С. 267–298.
      48. Peláez, T., Cercenado, E., Alcalá, L. et al. Metronidazole resistance in Clostridium diffi cile is heterogeneous // Journal of clinical microbiology. – 2008. – Т. 46. – № 9. – С. 3028–3032.
      49. Lebel S., Bouttier S., Lambert T. Th e cme gene of Clostridium diffi cile confers multidrug resistance in Enterococcus faecalis //FEMS microbiology letters. – 2004. – Т. 238. – № 1. – С. 93–100.
      50. Chopra I., Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance //Microbiology and molecular biology reviews. – 2001. – Т. 65. – № 2. – С. 232–260.
      51. Saxton, K., Baines, S. D., Freeman, J. et al. Eff ects of exposure of Clostridium diffi cile PCR ribotypes 027 and 001 to fl uoroquinolones in a human gut model // Antimicrobial agents and chemotherapy. – 2009. – Т. 53. – № 2. – С. 412–420.
      52. Jasni, A. S., Mullany, P., Hussain, H., Roberts, A. P. Demonstration of conjugative transposon (Tn5397)-mediated horizontal gene transfer between Clostridium diffi cile and Enterococcus faecalis //Antimicrobial agents and chemotherapy. – 2010. – Т. 54. – № 11. – С. 4924–4926.
      53. Knetsch, C. W., Connor, T. R., Mutreja, A. et al. Whole genome sequencing reveals potential spread of Clostridium diffi cile between humans and farm animals in the Netherlands, 2002 to 2011 //Euro surveillance: bulletin Europeen sur les maladies transmissibles= European communicable disease bulletin. – 2014. – Т. 19. – № 45. – С. 20954.
      54. Kuwata, Y., Tanimoto, S., Sawabe, E. et al. Molecular epidemiology and antimicrobial susceptibility of Clostridium diffi cile isolated from a university teaching hospital in Japan //European Journal of Clinical Microbiology & Infectious Diseases. – 2015. – Т. 34. – № 4. – С. 763–772.
      55. Mullane K. Fidaxomicin in Clostridium diffi cile infection: latest evidence and clinical guidance //Th erapeutic advances in chronic disease. – 2014. – Т. 5. – № 2. – С. 69–84.
      56. Hächler H., Berger-Bächi B., Kayser F. H. Genetic characterization of a Clostridium diffi cile erythromycin-clindamycin resistance determinant that is transferable to Staphylococcus aureus //Antimicrobial agents and chemotherapy. – 1987. – Т. 31. – № 7. – С. 1039–1045.
      57. Norman, K. N., Scott, H. M., Harvey, R. B. et al. Comparison of antimicrobial susceptibility among Clostridium diffi cile isolated from an integrated human and swine population in Texas //Foodborne pathogens and disease. – 2014. – Т. 11. – № 4. – С. 257–264.
      58. Norén, T., Åkerlund, T., Wullt, M. et al. Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium diffi cile //Antimicrobial agents and chemotherapy. – 2007. – Т. 51. – № 5. – С. 1840–1843.
      59. Campbell, E. A., Korzheva, N., Mustaev, A., et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase //Cell. – 2001. – Т. 104. – № 6. – С. 901–912.
      60. Aksoy D. Y., Unal S. New antimicrobial agents for the treatment of Gram‐positive bacterial infections //Clinical Microbiology and Infection. – 2008. – Т. 14. – № 5. – С. 411–420.
      61. Baines, S. D., Noel, A. R., Huscroft , G. S. et al. Evaluation of linezolid for the treatment of Clostridium diffi cile infection caused by epidemic strains using an in vitro human gut model //Journal of antimicrobial chemotherapy. – 2011. – Т. 66. – № 7. – С. 1537–1546.
      62. Ackermann, G., Tang, Y. J., Rodloff , A. C., et al. In vitro activity of sitafl oxacin against Clostridium diffi cile // Journal of Antimicrobial Chemotherapy. – 2001. – Т. 47. – № 5. – С. 722–724.
      63. Tenover F. C., Tickler I. A., Persing D. H. Antimicrobial-resistant strains of Clostridium diffi cile from North America //Antimicrobial agents and chemotherapy. – 2012. – Т. 56. – № 6. – С. 2929–2932.
      64. Marín, M., Martín, A., Alcalá, L. et al. Clostridium diffi cile isolates with high linezolid MICs harbor the multiresistance gene cfr //Antimicrobial agents and chemotherapy. – 2015. – Т. 59. – № 1. – С. 586–589.
      65. He, M., Miyajima, F., Roberts, P. et al. Emergence and global spread of epidemic healthcare-associated Clostridium diffi cile //Nature genetics. – 2013. – Т. 45. – № 1. – С. 109.
      66. Drudy, D., Quinn, T., O’mahony, R et al. High-level resistance to moxifl oxacin and gatifl oxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium diffi cile //Journal of Antimicrobial Chemotherapy. – 2006. – Т. 58. – № 6. – С. 1264–1267.
      67. Dridi, L., Tankovic, J., Burghoff er, B. et al. gyrA and gyrB mutations are implicated in cross-resistance to ciprofl oxacin and moxifl oxacin in Clostridium diffi cile // Antimicrobial agents and chemotherapy. – 2002. – Т. 46. – № 11. – С. 3418–3421.
      68. Ackermann, G., Tang, Y. J., Kueper, R., et al. Resistance to Moxifl oxacin in ToxigenicClostridium diffi cile Isolates Is Associated with Mutations in gyrA //Antimicrobial agents and chemotherapy. – 2001. – Т. 45. – № 8. – С. 2348–2353.
      69. Putsathit, P., Maneerattanaporn, M., Piewngam, P. et al. Antimicrobial susceptibility of Clostridium diffi cile isolated in Th ailand //Antimicrobial Resistance & Infection Control. – 2017. – Т. 6. – № 1. – С. 58.
      70. Linder, J. A., Huang, E. S., Steinman, M. A. et al. Fluoroquinolone prescribing in the United States: 1995 to 2002 // Th e American journal of medicine. – 2005. – Т. 118. – № 3. – С. 259–268.
      71. Vincent, Y., Manji, A., Gregory-Miller, K., Lee, C. A review of management of Clostridium diffi cile infection: Primary and recurrence //Antibiotics. – 2015. – Т. 4. – № 4. – С. 411–423.
      72. Smith C. J., Markowitz S. M., Macrina F. L. Transferable tetracycline resistance in Clostridium diffi cile //Antimicrobial agents and chemotherapy. – 1981. – Т. 19. – № 6. – С. 997–1003.
      73. Drudy, D., Kyne, L., O’Mahony, R. et al. gyrA mutations in fl uoroquinolone-resistant Clostridium diffi cile PCR-027 // Emerging infectious diseases. – 2007. – Т. 13. – № 3. – С. 504.
      74. Mena, A., Riera, E., López-Causapé, C. et al. In vivo selection of moxifl oxacin-resistant Clostridium diffi cile // Antimicrobial agents and chemotherapy. – 2012. – Т. 56. – № 5. – С. 2788–2789.
      75. Lee, J. H., Lee, Y., Lee, K. et al. Th e changes of PCR ribotype and antimicrobial resistance of Clostridium diffi cile in a tertiary care hospital over 10 years //Journal of medical microbiology. – 2014. – Т. 63. – № 6. – С. 819–823.
      76. Chaparro-Rojas F., Mullane K. M. Emerging therapies for Clostridium diffi cile infection–focus on fi daxomicin // Infection and drug resistance. – 2013. – Т. 6. – С. 41.
      77. Johnson A. P., Wilcox M. H. Fidaxomicin: a new option for the treatment of Clostridium diffi cile infection // Journal of antimicrobial chemotherapy. – 2012. – Т. 67. – № 12. – С. 2788–2792.
      78. Erikstrup, L. T., Danielsen, T. K. L., Hall, V. et al. Antimicrobial susceptibility testing of Clostridium diffi cile using EUCAST epidemiological cut‐off values and disk diff usion correlates //Clinical Microbiology and Infection. – 2012. – Т. 18. – № 8.
      79. Pirš, T., Avberšek, J., Zdovc, I et al. Antimicrobial susceptibility of animal and human isolates of Clostridium diffi cile by broth microdilution //Journal of medical microbiology. – 2013. – Т. 62. – № 9. – С. 1478–1485.
      80. Wasels, F., Spigaglia, P., Barbanti, F. et al. Integration of erm (B)-containing elements through large chromosome fragment exchange in Clostridium diffi cile //Mobile genetic elements. – 2015. – Т. 5. – № 1. – С. 12–16.
      81. Fraga E. G., Nicodemo A. C., Sampaio J. L. M. Antimicrobial susceptibility of Brazilian Clostridium diffi cile strains determined by agar dilution and disk diff usion // Brazilian Journal of Infectious Diseases. – 2016. – Т. 20. – № 5. – С. 476–481.
      82. Mullany, P., Wilks, M., Lamb, I. et al. Genetic analysis of a tetracycline resistance element from Clostridium diffi cile and its conjugal transfer to and from Bacillus subtilis // Microbiology. – 1990. – Т. 136. – № 7. – С. 1343–1349.
     


    Full text is published :
    Sukhina M. A., Makesheva A. B., Shelygin Yu. A., Kashnikov V. N. Mechanisms of antibacterial resistance of Clostridium (clostridioides) diffi cile (review). Experimental and Clinical Gastroenterology. 2018;160(12): 70–79. (In Russ.) DOI: 10.31146/1682-8658-ecg-160-12-70-79
    Read & Download full text